HOME >> BIOLOGY >> NEWS
Chikashi Toyoshima to present National Lecture at the Biophysical Society 51st Annual Meeting

The 7,800-member Biophysical Society is pleased to announce that Chikashi Toyoshima will deliver the National Lecture at the Biophysical Society 51st Annual Meeting in Baltimore, Maryland, March 3-7, 2007. Being named the National Lecturer is the Society's highest honor. Dr. Toyoshima is a professor at the Institute of Molecular and Cellular Biosciences at the University of Tokyo in Japan and was elected a Foreign Associate to the National Academy of Sciences in 2005.

Dr. Toyoshima's presentation, "Ion Pumping by Ca-ATPase of the Sarcoplasmic ReticulumA Structural View," will take place on Monday, March 5th at 8:00 PM in the Baltimore Convention Center.

The registration fee for the Annual Meeting includes entrance to the National Lecture. Those not registered for the Annual Meeting can buy tickets for the lecture onsite for $25.

The Biophysical Society's Annual Meeting is the world's largest meeting of biophysicists -- over 6,000 attendees are expected to converge on Baltimore to review the 3000+ posters and scientific talks scheduled to take place during the five-day event. Complete information about the Meeting can be found at http://www.biophysics.org/meetings/2007/.

For further information and press registration, contact: Ellen R. Weiss.


'"/>

Contact: Ellen R. Weiss
eweiss@biophysics.org
301-634-7176
Biophysical Society
12-Dec-2006


Page: 1

Related biology news :

1. Illinois researchers presenting at ASPB Annual Meeting in Chicago, July 7-11
2. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions
3. 18-year-old Singaporean student to present stem cell research paper at conferences in US and UK
4. WPI professor to represent American Mathematical Society at exhibition on science funding
5. SNM presents awards on Capitol Hill
6. Duetting birds with rhythm present a greater threat
7. ESA presents the sharpest ever satellite map of Earth
8. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
9. XDx to present recent success with AlloMap molecular expression testing
10. Data presented at ISHLT meeting confirm RNA analysis can identify rejection in lung transplant recip
11. Latest plant health research to be presented in San Diego

Post Your Comments:
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... dental biomaterial market will grow moderately through 2023 as ... and growing awareness of dental biomaterials all spur procedure ... such as China and ... bring dental procedures within reach for a larger proportion ...
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: